ResApp Health Limited (ASX: RAP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ResApp Health Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • ResApp Health Limited (ASX: RAP)
    Latest News

    Share Gainers

    Why Afterpay, Piedmont Lithium, ResApp, & Santos are charging higher

    Afterpay Ltd (ASX:APT) and ResApp Health Ltd (ASX:RAP) are two of four ASX shares charging notably higher on Friday. Here's why...

    Read more »

    jump in asx share price represented by man jumping in the air in celebration
    Share Gainers

    ResApp (ASX:RAP) share price jumps 19% on AstraZeneca deal

    The ResApp Health Ltd (ASX:RAP) share price is jumping on Friday after announcing a deal with AstraZeneca...

    Read more »

    covid asx share price represented by man in face mask giving thumbs up
    Share Gainers

    ResApp (ASX:RAP) share price jumps on COVID-19 app plans

    The ResApp Health Ltd (ASX:RAP) share price is surging higher today after announcing plans to trial a COVID-19 detection smartphone…

    Read more »

    Share Gainers

    Why Flight Centre, Qantas, ResApp, & Volpara are racing higher

    Flight Centre Travel Group Ltd (ASX:FLT) and Qantas Airways Limited (ASX:QAN) are two of four ASX shares racing higher on…

    Read more »

    falling asx share price represented by woman making sad face
    Share Market News

    Why the ResApp (ASX:RAP) share price is sinking 5% today

    The ResApp (ASX: RAP) share price is sinking today despite a positive announcement made to the ASX market. Here's the…

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Share Market News

    Why the ResApp (ASX:RAP) share price opened 10% higher today

    The ResApp (ASX:RAP) share price jumped more than 10% this morning before falling back to trade flat for the day…

    Read more »

    falling asx share price represented by woman making sad face
    Share Market News

    Here's why the Resapp (ASX:RAP) share price closed 5% lower

    The Resapp (ASX: RAP) share price closed 5% lower today after the company reported a loss in first-half FY21 results.…

    Read more »

    Share Market News

    Why the ResApp (ASX:RAP) share price is climbing higher

    The ResApp Health Ltd (ASX: RAP) share price is edging higher today after announcing an update on its prescription-only software…

    Read more »

    A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.
    Share Market News

    Here's why the ResApp (ASX:RAP) share price is climbing 6%

    The ResApp (ASX: RAP) share price is climbing higher today after the company released a positive update. Here's what ResApp…

    Read more »

    A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.
    Share Market News

    Why the ResApp (ASX:RAP) share price is edging higher

    The ResApp Health Ltd (ASX: RAP) share price is on the rise today after an update of its recent meeting…

    Read more »

    Share Market News

    Why the Resapp (ASX:RAP) share price stormed 5% higher today

    The Resapp Health Ltd (ASX: RAP) share price stormed 5.8% higher today following an announcement of a new partnership.

    Read more »

    Falling ASX share prices represented by girl falling asleep at her computer with her head in her hands
    Share Market News

    Why the ResApp (ASX:RAP) share price is falling 18% lower today

    The ResApp Health Ltd (ASX: RAP) share price is sinking more than 18% lower today following the company's release of…

    Read more »

    RAP ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Roger Aston Non-Executive ChairmanNon-Executive Director Jul 2015
    Dr Aston is a scientist and seasoned biotechnology entrepreneur. He has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include US Food and Drug Administration (FDA) and European Union (EU) product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston has also held Directorships/Chairmanships with Clinuvel Ltd, HalcyGen Ltd, and Ascent Pharma Ltd, was a member of the AusIndustry Biological Committee advising the Industry Research and Development Board.
    Dr Michael Stein Non-Executive Director Apr 2020
    Dr Stein is currently acting CEO of immuno-oncology company, Valo Therapeutics. Immediately prior to Valo, he was the founding CEO of OxStem Ltd, an award-winning biotechnology spinout from the University of Oxford. Dr Stein previously served as founding CEO for Doctor Care Anywhere, a UK-based telemedicine platform acquired by Synergix in 2015. In 2001, he cofounded the Map of Medicine with University College London and was founding CEO.
    Mr Brian Willoughby Leedman Executive Director Corporate Affairs May 2021
    Mr Leedman is a marketing and investor relations professional with over 15 years' experience in the biotechnology industry. Mr Leedman is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Ltd to form ResApp Health. Prior to ResApp, Mr Leedman co-founded Oncosil Medical Limited and Biolife Science (QLD) Limited (acquired by Imugene Limited).
    Mr Christopher Ntoumenopoulos Non-Executive Director Jan 2015
    Mr Ntoumenopoulos is the Managing Director of Twenty 1 Corporate. He has worked in financial markets for the past 15 years, focusing on Capital Raisings, Portfolio Management and Corporate Advisory. Mr Ntoumenopoulos has advised and funded numerous ASX companies from early stage venture capital, through to IPO.
    Dr Anthony (Tony) Keating Chief Executive OfficerManaging Director Jul 2015
    Dr Keating has over ten years' experience in commercialising technology. Dr Keating created the initial business strategy for ResApp and has led the commercialization of ResApp's technology to date. Previously, Dr Keating was Director, Commercial Engagement at UniQuest Pty Ltd, one of the global leaders in commercialisation of university technology. While at UniQuest, Dr Keating held roles as interim Chief Executive Officer and Non-Executive Director for a number of privately-held, venture-capital funded start-up companies.
    Ms Nicola (Nicki) Maxine Farley Company Secretary
    -
    Nicola (Nicki) Maxine Farley Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 90,509,172 10.53%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retail Client Drp> 46,498,352 5.41%
    J P Morgan Nominees Australia Pty Limited 22,398,291 2.61%
    Mr Frank Weng Thong Chew 18,453,000 2.15%
    HSBC Custody Nominees (Australia) Limited <GSCO Customers A/C> 17,974,966 2.09%
    BNP Paribas Noms Pty Ltd <DRP> 14,977,050 1.74%
    HSBC Custody Nominees (Australia) Limited GSCO ECA 12,567,531 1.46%
    Mr Yongsheng Peng & Mrs Yuezhen Xie 11,667,602 1.36%
    Mr Anthony James Keating 10,225,000 1.19%
    Citicorp Nominees Pty Limited 9,962,873 1.16%
    Equimetrixs Pty Ltd <The Newtonmore Superannuation fund A/C> 8,437,500 0.98%
    Narhex Life Sciences Developments Pty Ltd 7,997,005 0.93%
    CEM International (Asia) Pty Ltd 7,849,888 0.91%
    Norfolk Enchants Pty Ltd <Trojan Retirement Fund A/C> 7,510,228 0.87%
    Mr Trent Antony Goodrick 7,000,000 0.81%
    Queensland Forest Industries Pty Ltd 6,502,500 0.76%
    Mishtalem Pty Ltd 6,500,000 0.76%
    Super Dino Pty Ltd <Dino Super A/C> 5,430,779 0.63%
    HSBC Custody Nominees (Australia) Limited A/C 2 5,378,484 0.63%
    Paranji Super Fund Pty Ltd <Paranji Superfund A/C> 5,285,000 0.61%

    Profile

    since

    Note